Sydney, Australia, Oct 17, 2006 - (JCN Newswire) - Apollo Life Sciences (ASX: AOP), a Sydney-based biotechnology company, is pleased to announce that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies. The cream-based treatment, which relieves symptoms without an injection, is now proceeding to Phase 2 clinical trials.
